These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26788583)

  • 61. Assessment of the therapeutic value of new medicines marketed in Australia.
    Vitry AI; Shin NH; Vitre P
    J Pharm Policy Pract; 2013; 6():2. PubMed ID: 24764537
    [TBL] [Abstract][Full Text] [Related]  

  • 62. ANALYSIS OF MEDICINAL PROVISION OF PATIENTS WITH ARTERIAL HYPERTENSION IN HOSPITAL CONDITIONS.
    Sakhanda IV; Skrypnyk RL; Kosyachenko KL; Vlasenko OM; Kazmirchuk AP
    Wiad Lek; 2021; 74(3 cz 2):718-721. PubMed ID: 33843641
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Origin of First-in-Class Drugs: Innovation Versus Clinical Benefit.
    Osipenko L; Potey P; Perez B; Angelov F; Parvanova I; Ul-Hasan S; Mossialos E
    Clin Pharmacol Ther; 2024 Feb; 115(2):342-348. PubMed ID: 37983965
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Statement Issued by the Central Committee for State Registration in London: The Committee's Attitude Defined.
    Hospital (Lond 1886); 1916 Dec; 61(1592):207-208. PubMed ID: 29825153
    [No Abstract]   [Full Text] [Related]  

  • 65. One Health approach at the heart of the French Committee for monitoring and anticipating health risks.
    Lefrançois T; Lina B; ; Autran B
    Nat Commun; 2023 Nov; 14(1):7540. PubMed ID: 37990001
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacoeconomic research: the price of success.
    Felman I
    J Oncol Pract; 2006 Jan; 2(1):45. PubMed ID: 20871733
    [No Abstract]   [Full Text] [Related]  

  • 67. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative advantages of new drugs: French Pharmacoeconomic Committee is not sufficiently demanding.
    Prescrire Int; 2015 Dec; 24(166):303-7. PubMed ID: 26788583
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Towards better patient care: drugs to avoid in 2016.
    Prescrire Int; 2016 Apr; 25(170):105-11. PubMed ID: 27186626
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Penny and pound wise: pharmacoeconomics from a governmental perspective.
    van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
    Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reimbursement of targeted cancer therapies within 3 different European health care systems.
    Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
    Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.